Stocks › IART
Integra Lifesciences Holdings Corp (IART) stock analysis
SKIP 6% confidence · analysed Aug 19, 2026
This analysis is from Aug 19, 2026 and may be out of date.
On Aug 19, 2026, our model rated Integra Lifesciences Holdings Corp (IART) SKIP with 6% confidence at a price of $17.92. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 65, showing healthy upward momentum without being stretched.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.1x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $14.35 and the swing low is $8.70; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The PEG ratio is 0.67, which looks cheap relative to its expected growth.
The company reports a profit margin of -0.4% and revenue growth of +0.8%.
In its latest quarter it earned $0.56 per share, which beat the $0.48 analysts expected, with revenue +0.8% year over year.
Wall Street's average rating is 2.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "hold", with an average price target of $19.56.
The next earnings report is expected around Oct 29, 2026; prices often move sharply around earnings.
Research notes
Bull case: IART still screens as a low-valuation name, trading around 6.96x forward earnings versus much higher multiples for its peer group and below its five-year median, while recent estimates have ticked up and momentum has improved. The stock has also rallied strongly over the past year, and some analysts have recently become more constructive, including an upgrade to Buy with a $25** target from Argus.
Bear case: Analyst sentiment remains cautious overall, with consensus ratings around Reduce/Hold and a price target near the current share price, implying limited upside. The main concern is execution risk**: Zacks explicitly notes that the valuation discount reflects company-specific uncertainty, and the stock has also been described as still well below its 2021 peak.
Recent catalyst: The most recent catalyst appears to be a post-earnings / guidance-driven move and follow-through from analyst revisions, with the stock rising in early August as the company guided FY2026 EPS of $2.40–$2.50** and several analysts updated their views.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.06 (SKIP). Technicals: RSI 64.53, MACD bearish, price below SMA50. Fundamentals: PEG 0.67, margin -0.4%, revenue growth 0.8%. Financial results: YoY revenue +0.8%, last EPS surprise +16.7%, next earnings 2026-10-29. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bearish order block. FinGPT news read: neutral. Internet research: **Bull case:** IART still screens as a **low-valuation** name, trading around **6.96x forward earnings** versus much higher multiples for its peer group and below its five-year median, while recent estimates have ticked up and momentum has improved. The stock has also rallied strongly over the past year, and some analysts have recently become more constructive, including an upgrade to **Buy** with a **$25** target from Argus. **Bear case:** Analyst sentiment remains cautious overall, with consensus ratings around **Reduce/Hold** and a price target near the current share price, implying limited upside. The main concern is **execution risk**: Zacks explicitly notes that the valuation discount reflects company-specific uncertainty, and the stock has also been described as still well below its 2021 peak. **Recent catalyst:** The most recent catalyst appears to be a **post-earnings / guidance-driven move** and follow-through from analyst revisions, with the stock rising in early August as the company guided **FY2026 EPS of $2.40–$2.50** and several analysts updated their views. Reference price $17.91; no trade levels (SKIP).
Past ratings for IART
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Aug 19, 2026 | SKIP | 6% | $17.92 | — |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
ICLR · IRWD · JNJ · KMDA · LH · LLY · MDT · NRC · NVO · OSCR · PCRX · PGNY
Frequently asked questions
Is IART a buy right now?
As of Aug 19, 2026, our automated model rates Integra Lifesciences Holdings Corp (IART) SKIP with 6% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Integra Lifesciences Holdings Corp report earnings next?
The next earnings report is expected around Oct 29, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.